Drugs / VLA1601
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06334393 | Mar 2024 → Apr 2025 | Zika virus infectious disease | Valneva Austria GmbH | Completed | No outcome recorded |
| Phase 1 | NCT03425149 | Feb → Jun 2018 | Zika virus infectious disease | Valneva Austria GmbH | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VLA1601 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06334393 ↗ |
| Modality | Vaccine | “inactivated, whole Zika virus (ZIKV) vaccine candidate” NCT03425149 ↗ |
| Route | Intramuscular | “Each dose will be administered intramuscularly (i.m.)” NCT03425149 ↗ |